United Therapeutics Corporation (UTHR) Quick Ratio (Acid-Test): 6.28
Is United Therapeutics Corporation’s quick ratio (acid-test) high or low?
United Therapeutics Corporation's quick ratio (acid-test) of 6.28 is in line with its 5-year average of 6.48, around the middle of its 5-year range (4.28–9.55).
As of Saturday, June 13, 2026. 11.05% above its 12-month average of 5.66.
UTHR Quick Ratio (Acid-Test) Chart
UTHR Average Quick Ratio (Acid-Test) Chart
UTHR Current vs Average Quick Ratio (Acid-Test) Chart
UTHR Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
6.28
QUICK RATIO (ACID-TEST) AVG TTM
5.66
QUICK RATIO (ACID-TEST) AVG 3Y
6.29
QUICK RATIO (ACID-TEST) AVG 5Y
6.48
QUICK RATIO (ACID-TEST) AVG 10Y
5.31
QUICK RATIO (ACID-TEST) AVG 15Y
4.32
QUICK RATIO (ACID-TEST) AVG 20Y
4.80
CURRENT VS TTM AVG
+11.05%
CURRENT VS 3Y AVG
-0.08%
CURRENT VS 5Y AVG
-3.09%
CURRENT VS 10Y AVG
+18.21%
CURRENT VS 15Y AVG
+45.22%
CURRENT VS 20Y AVG
+30.94%
UTHR Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 6.28 | 5.66 | 6.29 | 6.48 |
| Waters Corporation (WAT) | $23.17B | 1.27 | 1.39 | 1.50 | 1.54 |
| BioNTech SE (BNTX) | $22.90B | 7.49 | 7.42 | 7.84 | 6.36 |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 0.81 | 0.77 | 0.77 | 0.79 |
| Labcorp Holdings Inc. (LH) | $21.83B | 1.23 | 1.27 | 1.23 | 1.37 |
| Veeva Systems Inc. (VEEV) | $25.92B | 4.89 | 4.70 | 4.39 | 4.08 |
| Moderna, Inc. (MRNA) | $19.80B | 3.22 | 3.42 | 3.19 | 2.63 |
| DexCom, Inc. (DXCM) | $29.08B | 1.59 | 1.44 | 1.80 | 2.83 |
| Hologic, Inc. (HOLX) | $16.97B | 3.06 | 3.04 | 3.12 | 2.66 |
| Biogen Inc. (BIIB) | $29.53B | 2.03 | 1.46 | 1.69 | 1.64 |
Liquidity Comparison
Quick Ratio
6.28
Excludes inventory
Current Ratio
6.60
Includes inventory
United Therapeutics Corporation Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for United Therapeutics Corporation (UTHR)?
- The quick ratio (acid-test) for UTHR stock is 6.28.
- Is United Therapeutics Corporation's quick ratio (acid-test) high or low?
- United Therapeutics Corporation's quick ratio (acid-test) of 6.28 is in line with its 5-year average of 6.48, around the middle of its 5-year range (4.28–9.55).
- What is the TTM average quick ratio (acid-test) for United Therapeutics Corporation (UTHR)?
- The TTM average quick ratio (acid-test) for UTHR stock is 5.66.
- What is the 3Y average quick ratio (acid-test) for United Therapeutics Corporation (UTHR)?
- The 3Y average quick ratio (acid-test) for UTHR stock is 6.29.
- What is the 5Y average quick ratio (acid-test) for United Therapeutics Corporation (UTHR)?
- The 5Y average quick ratio (acid-test) for UTHR stock is 6.48.
- What is the 10Y average quick ratio (acid-test) for United Therapeutics Corporation (UTHR)?
- The 10Y average quick ratio (acid-test) for UTHR stock is 5.31.
- What is the 15Y average quick ratio (acid-test) for United Therapeutics Corporation (UTHR)?
- The 15Y average quick ratio (acid-test) for UTHR stock is 4.32.
- What is the 20Y average quick ratio (acid-test) for United Therapeutics Corporation (UTHR)?
- The 20Y average quick ratio (acid-test) for UTHR stock is 4.80.
United Therapeutics Corporation Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 6.28 |
| 2024-12-31 | 5.03 |
| 2023-12-31 | 4.28 |
| 2022-12-31 | 9.55 |
| 2021-12-31 | 7.30 |
| 2020-12-31 | 6.44 |
| 2019-12-31 | 3.83 |
| 2018-12-31 | 6.03 |
| 2017-12-31 | 3.01 |
| 2016-12-31 | 3.98 |
| 2015-12-31 | 2.71 |
| 2014-12-31 | 1.80 |
| 2013-12-31 | 1.25 |
| 2012-12-31 | 3.57 |
| 2011-12-31 | 2.43 |
| 2010-12-31 | 1.70 |
| 2009-12-31 | 0.90 |
| 2008-12-31 | 4.90 |
| 2007-12-31 | 1.24 |
| 2006-12-31 | 13.78 |
| 2005-12-31 | 10.71 |
| 2004-12-31 | 7.39 |
| 2003-12-31 | 7.69 |
| 2002-12-31 | 14.47 |
| 2001-12-31 | 5.83 |
| 2000-12-31 | 19.08 |
| 1999-12-31 | 11.46 |
| 1998-12-31 | 9.33 |
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt